GlassScriptPhysician profile
Jeffrey K Bacon
NPI 1548485816
$49,596.25
in general payments reported to CMS, 2019-2025
35 companies · $4,824 in 2025
The $4,824 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $3,330 · 2021: $3,261 · 2022: $3,792 · 2023: $5,738 · 2024: $4,449 · 2025: $4,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $1,043 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,823.99 |
| Travel and Lodging | $1,043.18 |
| Education | $143.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $16,778.16 | 2019-2022 | |
| Amgen INC. | $9,714.99 | 2019-2025 | Enbrel, Krystexxa, Tavneos |
| Abbvie INC. | $6,377.29 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $3,061.91 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $2,188.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,575.22 | 2019-2025 | Benlysta, Shingrix |
| Horizon Therapeutics Plc | $1,550.35 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $1,224.50 | 2019-2025 | Orencia |
| US Oncology Corporate, INC. | $1,160.57 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $851.74 | 2021-2025 | Saphnelo |
| Pfizer INC. | $660.49 | 2019-2025 | |
| Lilly USA, LLC | $601.01 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $559.72 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $505.89 | 2019-2023 | Actemra, Rituxan |
| Ucb, INC. | $485.39 | 2019-2025 | Bimzelx, Cimzia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $405.81 | 2019 | |
| Radius Health, INC. | $309.64 | 2019-2025 | Tymlos |
| Genzyme Corporation | $290.28 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $233.39 | 2022-2025 | Purified Cortrophin Gel |
| Organon LLC | $227.30 | 2021-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $164.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.16 | 2023-2025 | Spevigo, Ofev |
| Mallinckrodt Enterprises LLC | $104.34 | 2019 | |
| Fresenius Kabi USA, LLC | $103.78 | 2023-2025 | Idacio |
| Mallinckrodt Hospital Products INC. | $87.12 | 2020-2025 | Acthar |
| Pacira Therapeutics, INC. | $58.88 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $46.41 | 2025 | |
| Tersera Therapeutics LLC | $27.65 | 2024 | Quzyttir |
| Biohaven Pharmaceuticals, INC. | $21.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.93 | 2022 | |
| Sandoz INC. | $19.13 | 2025 | Jubbonti |
| Bioventus LLC | $19.07 | 2019 | |
| Assertio Therapeutics, INC. | $18.10 | 2019 | |
| Oxford Immunotec USA INC | $17.19 | 2022 | |
| Octapharma USA, INC. | $16.23 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.